The Global Alzheimer’s disease drugs market size stood at around USD XX billion in 2019 and is projected to reach USD 2.206 billion by 2028, exhibiting a CAGR of XX% during the forecast period
Drug sales for Alzheimers Disease (AD) in 2018 were approximately $2.2B across the eight major markets. Over the forecast period, the market is expected to grow to $12.9B by 2028 at a CAGR of 19.3%. This growth will be driven by the increasing prevalence of AD and MCI worldwide, and the introduction of DMTs including Biogen’s aducanumab, Eisai’s BAN-2401, and Roche’s gantenerumab. This growth will be driven by the launch of eleven late-stage pipeline products.
The current competitive landscape in AD consists only of symptomatic treatments, of which there are currently six approved medications: three ChEIs (donepezil, rivastigmine, and galantamine), one NMDA-R antagonist (memantine), one combination therapy (memantine/donepezil), and one A A4 protein inhibitor (sodium oligomannate). Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments that are expected to occur within the next decade, could have a significant effect on the way the disease is managed. Earlier disease detection may render the currently available therapies more useful, but until disease-modifying agents are introduced, the landscape will not change significantly.